Glenmark Life Sciences Ltd

NSE
GLS •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Glenmark Life Sciences Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
35
TTM PE Ratio
Below industry Median
20.3
Price to Book Ratio
Above industry Median
4.9
Dividend yield 1yr %
Market Leader
5.1
TTM PEG Ratio
PEG TTM is less than 1
0.9
RSI
RSI is mid-range
54
MFI
MFI is mid-range
40.9

Glenmark Life Sciences Ltd shareholding Pattern

Promoter
82.8%
Foreign Institutions
4.6%
Mutual Funds
0.6%
Domestic Institutions
0.7%
Public
11.8%

Glenmark Life Sciences Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
8
Bearish Moving Averages
8
5Day EMA
871.20
10Day EMA
873.50
12Day EMA
872.80
20Day EMA
864.00
26Day EMA
853.60
50Day EMA
809.30
100Day EMA
745.20
200Day EMA
671.10
Delivery & Volume
Resistance & Support
860.67
Pivot
Resistance
First Resistance
869.28
Second Resistance
878.97
Third Resistance
887.58
Support
First Support
850.98
Second support
842.37
Third Support
832.68
Relative Strength Index
53.96
Money Flow Index
40.90
MACD
19.23
MACD Signal
26.64
Average True Range
25.39
Average Directional Index
18.97
Rate of Change (21)
0.34
Rate of Change (125)
35.23

Glenmark Life Sciences Ltd Company background

Founded in: 2011
Managing director: Yasir Yusufali Rawjee
The company was incorporated as Zorg Laboratories Private Limited, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune (RoC). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019.The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The companys RD facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh.During the year 201819, the company allotted 4,50,090 Equity Shares of Rs. 10/ each on the conversion of loan given to Director. During the year, 15,00,000 equity shares of the face value of Rs. 10 each fully paidup issued to Glenmark Pharmaceuticals Limited (Parent Company) pursuant to the Preferential Allotment. Subsequent to the quarter ended 30 June 2021, the company has completed the IPO of 21,022,222 equity shares comprising a fresh issue of 14,722,222 equity shares and offer for sale of 6,300,000 equity shares of face value of Rs 2 each at premium of Rs 718 per share aggregating to Rs 15,136 million. Pursuant to the IPO, the equity shares of the Company are listed on BSE Limited and National Stock Exchange of India Limited with effect from 06 August 2021.The Gross Debt comprising of Outstanding Purchase Consideration payable to the Parent Company was Rs 8,008.3 million as on 09 July 2021.The Company has repaid the whole of this remaining outstanding purchase consideration from the proceeds of the Fresh Issue pursuant to the IPO.
Read More

Glenmark Life Sciences Ltd FAQs

Glenmark Life Sciences Ltd shares are currently priced at 859.6 on NSE and 858.8 on BSE as of 2/29/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Glenmark Life Sciences Ltd [GLS] share was 129.28. The Glenmark Life Sciences Ltd [GLS] share hit a 1-year low of Rs. 370 and a 1-year high of Rs. 906.

The market cap of Glenmark Life Sciences Ltd is Rs. 10532.44 Cr. as of 2/29/2024 12:00:00 AM.

The PE ratios of Glenmark Life Sciences Ltd is 20.26 as of 2/29/2024 12:00:00 AM.

The PB ratios of Glenmark Life Sciences Ltd is 4.39 as of 2/29/2024 12:00:00 AM

The Mutual Fund Shareholding was 0.59% at the end of 2/29/2024 12:00:00 AM.

You can easily buy Glenmark Life Sciences Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage